Literature DB >> 10901687

The 'preliminary neuropsychological battery'. An instrument to grade the cognitive level of minimally responsive patients.

F M Cossa1, M Fabiani, A Farinato, M Laiacona, E Capitani.   

Abstract

An early, formalized cognitive evaluation of'minimally responsive' patients could be important in the planning of their care and rehabilitation as well as in providing a realistic prognosis and studying the modality of the cognitive recovery. A short, bedside, neuropsychologically-oriented test-battery, the Preliminary Neuropsychological Battery, a psychometric tool which enables the cognitive evaluation of these patients and of patients unable to give verbal or complex motor answers, has been devised. The BNP was administered to a sample of 40 head-injured patients and to a sample of 34 healthy subjects. The aim was (i) to evaluate its usefulness, and (ii) to study its correlation with cortical functions as assessed by a more extensive battery. The findings suggest that the BNP is useful for assessing the general cognitive level of head-injured post-comatose patients. It was able to detect patients deserving a wider, analytic, neuropsychological assessment. Attentional defects emerged as an important variable determining the BNP score.

Entities:  

Mesh:

Year:  1999        PMID: 10901687     DOI: 10.1080/026990599121322

Source DB:  PubMed          Journal:  Brain Inj        ISSN: 0269-9052            Impact factor:   2.311


  2 in total

1.  Reliability and validity of the severe impairment battery (SIB) in Korean dementia patients.

Authors:  Inn-Sook Ahn; Ji Hae Kim; Hyoung Mo Ku; Judith Saxton; Doh Kwan Kim
Journal:  J Korean Med Sci       Date:  2006-06       Impact factor: 2.153

2.  Reliability and validity of the severe impairment battery in Taiwanese patients with moderate to severe Alzheimer's disease.

Authors:  Mao-Hsuan Huang; Chia-Fen Tsai; Chaur-Jong Hu; Yu-Te Lin; Yuan-Han Yang; Wen-Fu Wang; Wei-Ju Lee; Jong-Ling Fuh
Journal:  J Chin Med Assoc       Date:  2020-11       Impact factor: 3.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.